1. Home
  2. MBBC vs ANVS Comparison

MBBC vs ANVS Comparison

Compare MBBC & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marathon Bancorp Inc.

MBBC

Marathon Bancorp Inc.

N/A

Current Price

$14.94

Market Cap

44.1M

Sector

Finance

ML Signal

N/A

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

N/A

Current Price

$0.92

Market Cap

48.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBBC
ANVS
Founded
1902
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.1M
48.2M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
MBBC
ANVS
Price
$14.94
$0.92
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $10.50
AVG Volume (30 Days)
1.4K
★ 3.0M
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 3200.00
39.39
EPS
★ 0.16
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$93.25
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.02
$0.62
52 Week High
$15.79
$5.50

Technical Indicators

Market Signals
Indicator
MBBC
ANVS
Relative Strength Index (RSI) 54.18 43.86
Support Level $14.58 $0.62
Resistance Level $15.39 $1.41
Average True Range (ATR) 0.16 0.14
MACD 0.05 -0.00
Stochastic Oscillator 100.00 35.61

Price Performance

Historical Comparison
MBBC
ANVS

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: